CD274 and small cell lung carcinoma: In this context, a randomized, double-blinded, Placebo-controlled phase II clinical study was conducted to investigate the efficacy of the combination therapy involving platinum-etoposide, the anti-PD-L1 antibody Atezolizumab, and the novel drug Trilaciclib in patients with advanced-stage SCLC (NCT03041311) [62,63].